A Once-in-a-Decade Opportunity 2 Magnificent SP 500 Stocks Down 37 percent and 28 percent to Buy Before 2025
| PCHM Stock | USD 3.05 0.00 0.00% |
About 61% of PharmChem's investor base is looking to short. The analysis of overall sentiment of trading PharmChem pink sheet suggests that many investors are alarmed at this time. PharmChem's investing sentiment overview a quick insight into current market opportunities from investing in PharmChem. Many technical investors use PharmChem stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
PharmChem pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of PharmChem daily returns and investor perception about the current price of PharmChem as well as its diversification or hedging effects on your existing portfolios.
PharmChem |
Two companies that fit this description now are animal healthcare specialists Idexx Laboratories and Zoetis . While Idexx is already one of my daughters core holdings and Zoetis is one of mine, I firmly agree that adding to your long-term winners over time is an outperforming proposition -- a notion espoused by Motley Fool co-founder David Gardner. Idexx and Zoetis are currently down 37 percent and 28, respectively, from their all-time highs -- yet theyre still beating the SP 500 on a total-return basis over the past decade.
Read at finance.yahoo.com
 |
PharmChem Fundamental Analysis
We analyze PharmChem's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PharmChem using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PharmChem based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
PharmChem is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
PharmChem Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with PharmChem pink sheet to make a market-neutral strategy. Peer analysis of PharmChem could also be used in its relative valuation, which is a method of valuing PharmChem by comparing valuation metrics with similar companies.
Peers
PharmChem Related Equities
| DHR | Danaher | 2.24 |
| ||
| A | Agilent Technologies | 2.53 |
| ||
| WAT | Waters | 3.56 |
| ||
| IDXX | IDEXX Laboratories | 3.82 |
| ||
| ILMN | Illumina | 6.35 |
|
Other Information on Investing in PharmChem Pink Sheet
PharmChem financial ratios help investors to determine whether PharmChem Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PharmChem with respect to the benefits of owning PharmChem security.